Finch Therapeutics Group Inc
FNCH
Market Cap$20.87M
Close$
$-3.70
129.2% downside
Current Fair Value
129.2% downsideOvervalued by 129.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $20.87 Million |
|---|---|
| Enterprise Value | $33.83 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-46.59 |
| Beta | 1.18 |
| Outstanding Shares | 1,605,763 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -2.4 |
|---|---|
| PEG | 7.87 |
| Price to Sales | 12.7 |
| Price to Book Ratio | 1.59 |
| Enterprise Value to Revenue | 11.89 |
| Enterprise Value to EBIT | -1.71 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.86 |
| Debt to Equity | 2.04 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Finch Therapeutics Group Inc
131 employeesFinch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery? platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and ta...